The Q-Line Biotech IPO is the public issue of Q-Line Biotech Limited, a company engaged in the manufacturing and supply of biotechnology products and laboratory solutions. Through this IPO, the company aims to raise capital to expand its business operations, strengthen manufacturing capabilities, and support future growth initiatives.
India’s biotechnology industry continues to grow with increasing investments in healthcare, pharmaceuticals, diagnostics, life sciences, and research. The rising adoption of advanced laboratory technologies, growing demand for quality healthcare products, and supportive government initiatives are creating favourable opportunities for companies operating in this sector.
Q-Line Biotech Limited focuses on manufacturing biotechnology products while maintaining quality standards, regulatory compliance, and efficient operational processes. The company serves pharmaceutical companies, diagnostic laboratories, research institutions, healthcare organisations, distributors, and other commercial customers through its established business network.
The proceeds from the public issue are proposed to be utilised for business expansion, capital expenditure, working capital requirements, and other corporate purposes as outlined in the offer document. These initiatives are expected to enhance the company’s operational efficiency and support its long-term growth strategy.
The Q-Line Biotech IPO offers investors an opportunity to participate in a company operating in India’s expanding biotechnology industry. However, investors should carefully evaluate the company’s financial performance, valuation, business model, industry outlook, future growth prospects, and the risks disclosed in the official offer documents before making an investment decision.
This detailed Q-Line Biotech IPO review covers IPO details, important dates, reservation, lot size, promoter holding, GMP, subscription status, allotment status, listing performance, company overview, financial information, objectives of the issue, strengths, risk factors, registrar details, and frequently asked questions.
Q-Line Biotech IPO Details
| Q-Line Biotech IPO Details | Information |
|---|---|
| IPO Name | Q-Line Biotech IPO |
| Company Name | Q-Line Biotech Limited |
| IPO Status | Listed |
| IPO Type | Book Built Issue |
| Category | SME IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹326 to ₹343 Per Share |
| Issue Size | ₹214.48 Crore |
| Fresh Issue | 62,53,200 Equity Shares |
| Offer for Sale | Nil |
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refund Initiation | 27 May 2026 |
| Shares Credited to Demat | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Listing Exchange | NSE SME |
| Lot Size | 400 Shares |
| Minimum Investment | ₹1,37,200 |
| Registrar | Bigshare Services Private Limited |
The Q-Line Biotech IPO comprises a fresh issue of equity shares, enabling the company to raise funds for its expansion plans and business requirements. As there is no offer for sale component, the entire net proceeds from the issue are intended to be utilised by the company for the objectives specified in the offer document.
After the subscription period concluded, the basis of allotment was finalised in accordance with the applicable regulatory process. Successful applicants received their allotted shares in their demat accounts before the listing date, while refunds were processed for unsuccessful applicants.
Before investing in the Q-Line Biotech IPO, investors should assess the company’s financial performance, business model, valuation, competitive position, industry outlook, and the risk factors mentioned in the Red Herring Prospectus (RHP).
Q-Line Biotech IPO Dates & Timeline
The Q-Line Biotech IPO followed the standard SME IPO process, beginning with the opening of the subscription window and concluding with the listing of the company’s equity shares on the NSE SME platform. After the issue closed, the registrar completed the allotment process, initiated refunds for unsuccessful applicants, and credited shares to successful investors before listing.
| Event | Date |
|---|---|
| IPO Opening Date | 21 May 2026 |
| IPO Closing Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refund Initiation | 27 May 2026 |
| Shares Credited to Demat Account | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Listing Exchange | NSE SME |
Investors who were allotted shares received them in their demat accounts before the listing date, while refunds for unsuccessful applications were processed according to the announced schedule.
Q-Line Biotech IPO Reservation
The Q-Line Biotech IPO allocated equity shares among different investor categories in accordance with the applicable SME IPO regulations. A separate allocation was also reserved for the market maker to facilitate liquidity after listing.
| Investor Category | Shares Reserved |
|---|---|
| Qualified Institutional Buyers (QIB) | 29,68,800 Equity Shares (47.47%) |
| Non-Institutional Investors (NII) | 8,90,400 Equity Shares (14.24%) |
| Retail Individual Investors (RII) | 20,79,600 Equity Shares (33.26%) |
| Market Maker | 3,14,400 Equity Shares (5.03%) |
| Total Issue Size | 62,53,200 Equity Shares |
The reservation structure allows participation from institutional, non-institutional, and retail investors while ensuring that the market maker receives a dedicated allocation to support post-listing liquidity.
Q-Line Biotech IPO Lot Size
The lot size specifies the minimum number of shares that investors could apply for during the IPO. Based on the upper price band of ₹343 per share, the minimum investment amount differed according to the investor category.
| Application Category | Lots | Shares | Investment Amount |
|---|---|---|---|
| Retail Minimum | 1 | 400 | ₹1,37,200 |
| Retail Maximum | 1 | 400 | ₹1,37,200 |
| HNI/NII Minimum | 2 | 800 | ₹2,74,400 |
Retail investors could apply for one lot, while applications exceeding the retail investment limit were considered under the Non-Institutional Investor category.
Q-Line Biotech IPO Promoter Holding
Before the public issue, the promoters held a substantial ownership stake in the company. Following the fresh issue of equity shares, the promoter shareholding reduced due to dilution arising from the issue of new shares, while the promoters continued to retain management control.
| Particulars | Details |
|---|---|
| Promoter Holding Before IPO | 99.99% |
| Promoter Holding After IPO | 74.95% |
The reduction in promoter shareholding resulted from the fresh issue of equity shares and not from an offer for sale by the promoters.
Q-Line Biotech IPO GMP
The Grey Market Premium (GMP) is an unofficial indicator that reflects the premium or discount at which IPO shares are traded before their stock exchange listing. Since grey market transactions are not regulated, GMP should be considered only as an indication of prevailing market sentiment rather than a guarantee of listing performance.
Ahead of listing, the Q-Line Biotech IPO attracted positive interest in the grey market. However, investors should evaluate the company’s financial performance, valuation, business fundamentals, and long-term growth prospects instead of relying solely on GMP while making investment decisions.
Q-Line Biotech IPO Subscription Status
The subscription status indicates the demand received from different investor categories during the IPO bidding period. It provides an overview of investor participation across institutional, non-institutional, and retail segments.
| Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 11.38x |
| Non-Institutional Investors (NII) | 40.82x |
| Retail Individual Investors (RII) | 33.21x |
| Total Subscription | 24.67x |
The Q-Line Biotech IPO witnessed strong demand across all investor categories. The robust subscription levels reflected healthy investor participation during the bidding period. However, subscription figures alone should not be considered the sole basis for an investment decision, and investors should also evaluate the company’s financial performance, valuation, business model, and future growth prospects.
Q-Line Biotech IPO Allotment Status
The allotment process for the Q-Line Biotech IPO was completed after the subscription window closed. All valid applications were processed in accordance with the applicable regulatory guidelines before the basis of allotment was finalised.
Applicants could check their allotment status through the registrar’s official website by entering their PAN, application number, or DP/Client ID. Shares allotted to successful applicants were credited to their demat accounts before the listing date, while refunds were initiated for applicants who did not receive an allotment.
Q-Line Biotech IPO Listing Performance
The equity shares of Q-Line Biotech Limited were listed on the NSE SME platform following the completion of the IPO process. The listing performance reflects the market’s initial response to the company’s public issue.
| Particulars | Details |
|---|---|
| Issue Price | ₹343 Per Share |
| Listing Price | ₹380.00 Per Share |
| Listing Gain | ₹37.00 Per Share |
| Listing Gain (%) | 10.79% |
| Closing Price on Listing Day | ₹399.00 Per Share |
The shares debuted at a premium over the issue price, providing positive listing gains to successful applicants. The stock also closed above its listing price on the first trading day, indicating favourable investor participation after listing.
About Q-Line Biotech Limited
Q-Line Biotech Limited is engaged in the manufacturing and supply of biotechnology products, laboratory reagents, diagnostic solutions, and research-related products. The company caters to pharmaceutical companies, healthcare institutions, diagnostic laboratories, research organisations, educational institutions, and industrial customers across India.
The company focuses on developing high-quality products by following established manufacturing processes and quality control systems. Its operations cover product development, manufacturing, packaging, quality assurance, and distribution, enabling it to serve a broad customer base with reliable biotechnology solutions.
Q-Line Biotech Limited places significant emphasis on product quality, regulatory compliance, research capabilities, and customer satisfaction. Its manufacturing facilities are designed to maintain consistent quality standards while supporting the growing demand for biotechnology and laboratory products.
With increasing investments in healthcare, diagnostics, pharmaceutical research, and life sciences, the company aims to strengthen its market position through continuous product development, operational improvements, and expansion of its distribution network.
Business Model
Q-Line Biotech Limited follows an integrated business model that combines product development, manufacturing, quality assurance, and distribution of biotechnology products. The company focuses on delivering reliable laboratory and healthcare solutions while maintaining operational efficiency and regulatory compliance.
The major components of the company’s business model include:
- Product Development – The company develops biotechnology products and laboratory solutions designed to meet the requirements of healthcare, research, and industrial customers.
- Manufacturing Operations – Modern manufacturing processes and quality control systems help ensure consistency, reliability, and compliance with applicable standards.
- Quality Assurance – Products undergo multiple quality checks before dispatch to maintain high standards of performance and customer satisfaction.
- Distribution Network – The company supplies its products through distributors, institutional customers, healthcare organisations, pharmaceutical companies, and research laboratories across different regions.
- Research and Innovation – Continuous focus on product improvement and innovation enables the company to expand its product portfolio and meet changing industry requirements.
The company’s future growth strategy focuses on expanding manufacturing capacity, strengthening research capabilities, broadening its product range, and increasing its presence in the biotechnology and life sciences industry.
Product Portfolio
Q-Line Biotech Limited offers a broad portfolio of biotechnology products designed to serve the requirements of research laboratories, healthcare institutions, pharmaceutical companies, diagnostic centres, educational institutions, and industrial customers. The company focuses on delivering reliable products that meet quality standards while supporting scientific research, diagnostics, and laboratory applications.
The company’s major product categories include:
- Laboratory Reagents – A range of reagents used for laboratory testing, research activities, and analytical applications.
- Diagnostic Products – Products developed to support clinical diagnostics, healthcare laboratories, and medical testing requirements.
- Research Chemicals and Consumables – Various chemicals and laboratory consumables supplied for research, academic, and industrial applications.
- Biotechnology Products – Specialised biotechnology solutions designed for pharmaceutical, healthcare, and life science applications.
- Laboratory Equipment and Accessories – Selected laboratory equipment and related accessories supplied to research institutions, diagnostic laboratories, and educational organisations.
By expanding its product offerings and maintaining quality standards, Q-Line Biotech Limited aims to strengthen its position within India’s growing biotechnology industry.
Industry Overview
India’s biotechnology industry has emerged as one of the fastest-growing segments of the healthcare and life sciences sector. Increasing investment in pharmaceuticals, healthcare infrastructure, diagnostics, research, and innovation has created significant opportunities for biotechnology companies across the country.
The sector is supported by rising healthcare expenditure, favourable government initiatives, expanding research activities, and increasing demand for advanced diagnostic and laboratory products. Growth in pharmaceutical manufacturing, medical research, vaccine development, and biotechnology-based healthcare solutions continues to drive demand for specialised products and services.
The expansion of research institutions, hospitals, educational organisations, and diagnostic laboratories has further increased the need for reliable biotechnology products, laboratory reagents, and scientific equipment. Technological advancements and growing emphasis on quality standards are also contributing to the organised growth of the industry.
Despite favourable long-term prospects, the biotechnology sector is subject to challenges such as stringent regulatory requirements, rapid technological changes, product validation standards, research and development costs, and increasing competition. Companies with strong product quality, regulatory compliance, research capabilities, and efficient manufacturing processes are generally better positioned to achieve sustainable growth.
With continued investments in healthcare, pharmaceuticals, diagnostics, and scientific research, India’s biotechnology industry is expected to remain an important contributor to the country’s healthcare ecosystem and economic development.
Q-Line Biotech IPO Financial Information
The financial performance of Q-Line Biotech Limited provides insight into the company’s operational growth, profitability, and financial position over the reported financial years. Analysing the financial statements helps investors understand revenue trends, earnings performance, asset growth, and the company’s overall financial health before making an investment decision.
The financial information presented below has been compiled from the company’s restated financial statements included in the offer document.
Statement of Assets, Liabilities and Equity
| Particulars (₹ in Crore) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 151.84 | 116.37 | 84.26 |
| Total Liabilities | 64.58 | 53.71 | 41.62 |
| Total Equity (Net Worth) | 87.26 | 62.66 | 42.64 |
The balance sheet reflects consistent growth in total assets and shareholders’ equity during the reported financial years. The company’s expanding net worth alongside business growth indicates a strengthening financial position.
Statement of Profit and Loss
| Particulars (₹ in Crore) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue from Operations | 219.63 | 167.45 | 122.89 |
| EBITDA | 47.82 | 34.18 | 23.44 |
| Profit Before Tax (PBT) | 39.51 | 27.64 | 18.57 |
| Profit After Tax (PAT) | 29.46 | 20.63 | 13.82 |
The company has reported healthy growth in revenue and profitability over the reported period, reflecting improved operational performance and business expansion.
Q-Line Biotech IPO Key Financial Ratios
| Ratio | FY2025 |
|---|---|
| EBITDA Margin | 21.77% |
| PAT Margin | 13.41% |
| Return on Equity (ROE) | 33.76% |
| Return on Capital Employed (ROCE) | 31.48% |
| Debt to Equity Ratio | 0.74 |
| Earnings Per Share (EPS) (₹) | 16.58 |
| Net Asset Value (NAV) (₹) | 49.10 |
The above financial ratios provide an overview of the company’s profitability, capital efficiency, financial leverage, and earnings performance. Investors should evaluate these metrics together with the company’s business model, valuation, industry outlook, and future growth strategy before making an investment decision.
Q-Line Biotech IPO Objects of the Issue
The Q-Line Biotech IPO has been launched to raise funds for strengthening the company’s business operations, expanding infrastructure, and supporting future growth plans. The net proceeds from the issue are proposed to be utilised for the purposes mentioned in the offer document.
The key objectives of the issue include:
- Funding Capital Expenditure – A portion of the IPO proceeds will be utilised towards purchasing equipment, upgrading infrastructure, and enhancing manufacturing capabilities to support increased business operations.
- Working Capital Requirements – The company intends to use part of the funds to meet working capital requirements, including procurement of raw materials, inventory management, and regular operational expenses.
- Expansion of Business Operations – The proceeds will support the company’s plans to expand its product portfolio, improve operational capacity, and strengthen its market presence.
- General Corporate Purposes – A portion of the funds will be allocated towards general business requirements, administrative expenses, and other corporate initiatives.
- Issue Related Expenses – Part of the proceeds will be used to meet expenses associated with the IPO process.
The planned utilisation of IPO proceeds is expected to improve the company’s operational capabilities, strengthen financial flexibility, and support its long-term growth objectives in the biotechnology and healthcare sector.
Q-Line Biotech IPO Strengths
Q-Line Biotech Limited operates in the growing biotechnology and healthcare sector with a focus on product quality, manufacturing capabilities, and customer relationships. Some of the company’s key strengths include:
- Presence in Growing Biotechnology Sector – The company operates in an industry supported by increasing demand for healthcare solutions, diagnostics, research products, and laboratory technologies.
- Diversified Product Portfolio – Q-Line Biotech offers various biotechnology products, laboratory solutions, and related products catering to multiple customer segments.
- Strong Customer Base – The company serves pharmaceutical companies, research institutions, diagnostic laboratories, healthcare organisations, and other commercial customers.
- Focus on Quality and Compliance – Quality control systems and regulatory compliance practices help maintain product reliability and customer confidence.
- Experienced Management Team – The promoters and management team possess industry knowledge and experience, supporting strategic business decisions and operational growth.
- Research and Innovation Focus – Continuous improvement in products and processes helps the company adapt to changing industry requirements.
- Growing Market Opportunities – Increasing investments in healthcare infrastructure, pharmaceutical research, and diagnostics provide opportunities for future business expansion.
- Scalable Business Model – The company’s focus on expanding manufacturing capacity, strengthening distribution, and increasing product offerings provides potential for long-term growth.
Q-Line Biotech IPO Risk Factors
Investors should carefully consider the following risks associated with Q-Line Biotech Limited before making an investment decision:
- Regulatory Risks – Biotechnology and healthcare companies must comply with strict regulatory requirements, and any changes in regulations may impact business operations.
- Intense Competition – The company operates in a competitive industry with several established domestic and international players.
- Dependence on Research and Technology Development – The company’s growth may depend on its ability to continuously improve products and adopt new technologies.
- Working Capital Requirements – The business requires adequate working capital for procurement, manufacturing, inventory maintenance, and operational activities.
- Product Quality and Compliance Risks – Any failure to maintain quality standards or comply with applicable regulations may affect reputation and business performance.
- Supply Chain Dependence – Delays in sourcing raw materials or disruptions in supply chains may impact manufacturing and delivery schedules.
- Customer Concentration Risk – Dependence on certain customers or customer groups may affect revenue stability if business relationships change.
- SME Listing Risks – Shares listed on the SME platform may experience lower liquidity and higher volatility compared to companies listed on the main board.
Q-Line Biotech IPO Registrar Details
The registrar manages IPO-related activities including processing applications, finalising allotment, handling refunds, crediting shares to investors’ demat accounts, and resolving investor queries.
| Particulars | Details |
|---|---|
| Registrar | Bigshare Services Private Limited |
| Website | https://www.bigshareonline.com |
| [email protected] | |
| Investor Helpline | +91-22-6263 8200 |
Investors can contact the registrar for queries related to IPO applications, allotment status, refunds, demat credit, and other issue-related matters.
Q-Line Biotech IPO Conclusion
The Q-Line Biotech IPO provides investors an opportunity to participate in a company operating in India’s expanding biotechnology and healthcare ecosystem. The company has developed its business around biotechnology products, laboratory solutions, quality-focused manufacturing, and customer-oriented operations.
The funds raised through the IPO are expected to support business expansion, infrastructure development, working capital requirements, and other corporate objectives. These initiatives may help the company improve operational efficiency and strengthen its market position.
However, investors should also evaluate various risks, including regulatory requirements, competition, technology dependence, working capital needs, and SME market-related risks before making an investment decision.
Overall, the Q-Line Biotech IPO should be analysed based on the company’s financial performance, valuation, industry outlook, business strategy, growth opportunities, and risk factors mentioned in the offer document.
Q-Line Biotech IPO FAQs
What is the Q-Line Biotech IPO?
The Q-Line Biotech IPO is a Book Built SME public issue through which Q-Line Biotech Limited raised funds to support business expansion, operational requirements, and future growth initiatives.
What was the price band of the Q-Line Biotech IPO?
The price band of the Q-Line Biotech IPO was ₹326 to ₹343 per equity share.
What was the minimum lot size for the Q-Line Biotech IPO?
The minimum application size was 400 equity shares, requiring an investment of ₹1,37,200 at the upper price band.
On which stock exchange are Q-Line Biotech shares listed?
The equity shares of Q-Line Biotech Limited are listed on the NSE SME platform.
Who was the registrar for the Q-Line Biotech IPO?
Bigshare Services Private Limited was the official registrar for the Q-Line Biotech IPO.
What were the objectives of the Q-Line Biotech IPO?
The IPO proceeds were proposed to be utilised for capital expenditure, working capital requirements, business expansion, general corporate purposes, and issue-related expenses.
What are the major risks associated with the Q-Line Biotech IPO?
Key risks include regulatory requirements, industry competition, technology changes, working capital needs, supply chain challenges, product quality requirements, and SME listing-related risks.
Should investors consider investing in the Q-Line Biotech IPO?
Investors should evaluate the company’s financial performance, valuation, business model, industry growth potential, and associated risks before making any investment decision.
